The CV benefit of statins can be partly explained by their ability to inhibit of HMG-CoA reductase, which subsequently lowers cholesterol and decreases the formation of mevalonate. However ...

NEW YORK, August 15 (Praxis Press). Animal studies and some cohort studies in humans have raised concerns about the carcinogenicity of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase ...

The enzyme is known as HMG-CoA reductase, and to doctors, it is not obscure. It is, in fact, the very enzyme that statins block in the process of halting cholesterol production. And so ...

3-hydroxy-3-methyl-glutaryl-CoA (HMG-CoA) reductase, the rate-limiting enzyme in the cholesterol biosynthetic pathway, was an attractive target in the search for drugs to reduce plasma cholesterol ...

18 Anti–HMG-CoA reductase autoantibodies may also be present in patients with autoimmune myopathy who have never been prescribed statin therapy. 8,10,17,23 Such patients, who made up one third ...

Please provide your email address to receive an email when new articles are posted on . Genetic inhibition of HMG-CoA reductase, a state that mimics long-term statin use, was associated with ...

HMG-CoA reductase inhibitors, commonly referred to as statins, are the cornerstone of pharmacologic reduction of elevated low-density lipoprotein cholesterol. LDL-C is the main contributor to ...

Purpose: Clinical trials evaluating the effectiveness of therapy with hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitors for reducing elevated C-reactive protein (CRP) levels and ...

Isoprenoid-mediated suppression of HMG CoA reductase in tumors was previously correlated to growth arrest; the latter was attenuated by supplemental mevalonate. "This is the first time that ...